A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy
- PMID: 27773399
- PMCID: PMC5079133
- DOI: 10.1016/j.ihj.2016.02.007
A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy
Abstract
Objective: Alcohol septal ablation (ASA) is a therapeutic alternative to surgical myectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM). However, the anatomical variability of the septal branch, risk of complete heart block, and late onset ventricular arrhythmias are limitations to its therapeutic usage. There is recent interest in the use of radiofrequency catheter ablation (RFCA) as a therapeutic option in HOCM. We aimed to assess the safety and efficacy of RFCA in the treatment of symptomatic HOCM.
Methods: Seven patients with symptomatic HOCM (mean age 43.7±15.6 years, five males), and significant left ventricular outflow tract (LVOT) gradient despite optimal drug therapy, underwent ablation of the hypertrophied interventricular septum. These patients had unfavorable anatomy for ASA. Ablation was performed under 3D electro-anatomical system guidance using an open irrigated tip catheter. The region of maximal LV septal bulge as seen on intracardiac echocardiography was targeted. Patients were followed up at 1, 6, and 12 months post-procedure.
Results: The mean baseline LVOT gradient by Doppler echocardiography was 81±14.8mm of Hg which reduced to 48.5±22.6 (p=0.0004), 49.8±19.3 (p=0.0004), and 42.8±26.1mm of Hg (p=0.05) at 1, 6, and 12 months respectively. Symptoms improved at least by one NYHA class in all but one patient. One patient developed transient pulmonary edema post-RFA. There were no other complications.
Conclusion: RFCA of the hypertrophied septum causes sustained reduction in the LVOT gradient and symptomatic improvement among patients with HOCM. Electroanatomical mapping helps to perform the procedure safely.
Keywords: Alcohol septal ablation; Hypertrophic obstructive cardiomyopathy; Left ventricular outflow tract; Radiofrequency ablation.
Copyright © 2016 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
Figures



Similar articles
-
Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy.Heart Rhythm. 2016 Sep;13(9):1885-90. doi: 10.1016/j.hrthm.2016.04.018. Epub 2016 Apr 27. Heart Rhythm. 2016. PMID: 27132152
-
Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound® technology to guide ablation.Europace. 2016 Jan;18(1):113-20. doi: 10.1093/europace/euv302. Epub 2015 Nov 4. Europace. 2016. PMID: 26541709
-
Ablation of hypertrophic septum using radiofrequency energy: an alternative for gradient reduction in patient with hypertrophic obstructive cardiomyopathy?J Invasive Cardiol. 2013 Jun;25(6):E128-32. J Invasive Cardiol. 2013. PMID: 23735367
-
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.J Interv Cardiol. 2006 Aug;19(4):319-27. doi: 10.1111/j.1540-8183.2006.00153.x. J Interv Cardiol. 2006. PMID: 16881978
-
Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy.Z Kardiol. 2000;89 Suppl 4:IV41-54. doi: 10.1007/s003920070062. Z Kardiol. 2000. PMID: 10810776 Review.
Cited by
-
Endocardial Radiofrequency Ablation vs. Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and Meta-Analysis.Front Surg. 2022 Apr 26;9:859205. doi: 10.3389/fsurg.2022.859205. eCollection 2022. Front Surg. 2022. PMID: 35558385 Free PMC article.
-
A modified endocardial radiofrequency ablation approach for hypertrophic obstructive cardiomyopathy guided by transthoracic echocardiography: a case series.Ann Transl Med. 2021 Jun;9(12):1006. doi: 10.21037/atm-21-2783. Ann Transl Med. 2021. PMID: 34277806 Free PMC article.
-
Review of Contemporary Invasive Treatment Approaches and Critical Appraisal of Guidelines on Hypertrophic Obstructive Cardiomyopathy: State-of-the-Art Review.J Clin Med. 2022 Jun 14;11(12):3405. doi: 10.3390/jcm11123405. J Clin Med. 2022. PMID: 35743475 Free PMC article. Review.
-
A Narrative Review of Emerging Therapies for Hypertrophic Obstructive Cardiomyopathy.Curr Cardiol Rev. 2023;19(4):e240323214927. doi: 10.2174/1573403X19666230324102828. Curr Cardiol Rev. 2023. PMID: 36999417 Free PMC article. Review.
-
Efficacy and safety of myectomy and radiofrequency septal ablation for treating hypertrophic obstructive cardiomyopathy.Open Heart. 2025 Apr 4;12(1):e003166. doi: 10.1136/openhrt-2025-003166. Open Heart. 2025. PMID: 40185503 Free PMC article.
References
-
- Maron B.J. Hypertrophic cardiomyopathy. Lancet. 1997;350:127–133. - PubMed
-
- Gersh B.J., Maron B.J., Bonow R.O. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2011;142:e153–e203. - PubMed
-
- Alam M., Dohainish H., Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interv Cardiol. 2006;19:319–327. - PubMed
-
- Fernandes V.L., Nielsen C., Nagueh S.F. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC: Cardiovasc Interv. 2008;1:561–570. - PubMed
-
- Kuhn H., Lawrenz T., Lieder F. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol. 2008;97:234–243. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources